证券代码：688358 证券简称：祥生医疗 公告编号：2025-020 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 本次减持股东的基本情况 本次减持计划实施前，无锡祥生医疗科技股份有限公司（以下简称"祥生医 疗"或"公司"）股东无锡祥鼎投资企业（有限合伙）（以下简称"祥鼎投资"）持有 公司股份 4,704,000 股，占公司总股本的 4.20%；股东上海御德科技有限公司（以 下简称"上海御德"）持有公司股份 1,679,956 股，占公司总股本的 1.50%；股东 无锡祥鹏投资企业（有限合伙）（以下简称"祥鹏投资"）持有公司股份 1,344,000 股，占公司总股本的 1.20%。 上述股份均为无限售流通股，来源于公司首次公开发行前取得的股份以及公 司实施资本公积转增股本取得的股份，涉及公司首次公开发行前取得的股份已于 2022 年 12 月 3 日解除限售并上市流通。 减持计划的实施结果情况 2025 年 4 月 28 日，公司披露了《无锡祥生医疗科技股份有限公司股东减持 股份计划公告》， ...

Core Viewpoint - Xiangsheng Medical (688358.SH) announced that its shareholders, Xiangding Investment, Shanghai Yude, and Xiangpeng Investment, did not reduce their holdings during the designated reduction period, which ends on August 21, 2025 [1] Summary by Relevant Categories - Company Actions - The company received a notification letter regarding the reduction plan [1] - The reduction plan period has now expired without any shares being sold by the mentioned shareholders [1]

近日，祥生医疗（688358）发布股东减持计划时间届满暨减持股份结果公告。此前，股东祥鼎投资、上 海御德、祥鹏投资分别计划减持不超1.05%、0.37%、0.30%的公司股份。截至2025年8月21日减持期限 届满，三股东均未减持公司股份。减持前，祥鼎投资、上海御德、祥鹏投资分别持股4,704,000股、 1,679,956股、1,344,000股，占总股本比例分别为4.20%、1.50%、1.20%。本次实际减持情况与此前披露 的减持计划一致，且未提前终止减持计划。 ...

祥生医疗属于医疗器械行业，专注于超声医学影像设备的研发、生产和销售，产品涵盖全数字超声诊断 系统及相关技术服务。 截至2025年8月20日收盘，祥生医疗股价报34.16元，较前一交易日上涨0.24元，涨幅0.71%。当日成交 量为14824手，成交额0.50亿元，振幅2.18%。 来源：金融界 资金流向方面，8月20日主力资金净流出140万元，占流通市值的0.04%。近五个交易日累计净流出 2382.58万元，占流通市值的0.62%。 风险提示：股市有风险，投资需谨慎。 ...

Core Viewpoint - Xiangsheng Medical (688358) has shown a slight increase in stock price, with a closing price of 33.92 yuan on August 19, 2025, reflecting a 0.95% rise, amidst mixed capital flows [1][2]. Financial Performance - The company reported a main revenue of 128 million yuan for Q1 2025, a year-on-year decrease of 9.16% [3]. - The net profit attributable to shareholders was 41.61 million yuan, down 8.62% year-on-year [3]. - The net profit after deducting non-recurring items was 38.87 million yuan, a decline of 13.38% year-on-year [3]. - The company's debt ratio stands at 9.84% [3]. Market Position - Xiangsheng Medical's total market capitalization is 3.803 billion yuan, significantly lower than the industry average of 12.117 billion yuan, ranking 95th out of 123 in the medical device industry [3]. - The company's net assets amount to 1.462 billion yuan, compared to the industry average of 3.898 billion yuan, ranking 86th [3]. - The price-to-earnings ratio (P/E) is 22.85, which is considerably lower than the industry average of 81.45, ranking 13th [3]. - The price-to-book ratio (P/B) is 2.82, compared to the industry average of 4.08, ranking 57th [3]. - The gross margin is 61.33%, higher than the industry average of 51.3%, ranking 48th [3]. - The net margin is 32.58%, significantly above the industry average of 10.7%, ranking 13th [3]. - Return on equity (ROE) is 2.89%, compared to the industry average of 1.28%, ranking 27th [3]. Capital Flow Analysis - On August 19, 2025, the net inflow of main funds was 2.2215 million yuan, accounting for 2.85% of the total transaction amount [1][2]. - Retail investors contributed a net inflow of 1.0292 million yuan, representing 1.32% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with notable outflows from retail and speculative funds on certain days [2].

记者金音,见习记者彭康一 据投资快报梳理统计，上周（8月11日至8月17日）A股市场共有124家上市公司披露股东减持计划，合 计拟套现金额达到167.28亿元。此次减持涉及计算机、通信和其他电子设备制造业、专用设备制造业、 电气机械和器材制造业等37个行业，既有控股股东、高管等内部人士，也包括私募股权基金、产业投资 机构等外部股东。若按公告日收盘价计算，此次拟减持的金额区间跨度较大，最高拟减持金额达到9.41 亿元，最低拟减持金额为4.43万元。 进一步分析减持比例，计划减持比例达到3%及以上的企业有28家，涉及金额达58.68亿元，占总金额的 35.08%；计划减持比例在1%～3%（不含3%）之间的企业有52家，涉及金额达到97.07亿元，占总金额 的58.03%；计划减持比例在1%以下的企业达到44家，涉及金额仅为11.53亿元，占总金额的6.89%。 根据同花顺iFinD数据，上周发布减持计划的124家公司分布于37个证监会(新)一级行业，其中计算机、 通信和其他电子设备制造业（24家）、专用设备制造业（13家）、软件和信息技术服务业（12家）位居 减持企业数量前三，合计占比达39.52%。若按计划减持 ...

Group 1 - The core stock price of Xiangsheng Medical (688358) closed at 33.25 yuan on August 15, 2025, down 1.77% with a turnover rate of 3.63% and a trading volume of 40,700 shares, resulting in a transaction amount of 133 million yuan [1] - On August 15, the net outflow of main funds was 16.81 million yuan, accounting for 12.62% of the total transaction amount, while retail investors had a net inflow of 16.88 million yuan, accounting for 12.67% of the total transaction amount [4] - The company announced that its actual controller, chairman, and senior management personnel, Mo Ruoli, plan to reduce their holdings by no more than 3,363,735 shares, which is 3.00% of the total share capital, within three months starting from 15 trading days after the announcement [3][4] Group 2 - The company does not currently engage in research related to brain-machine interface technology, despite investor inquiries about its potential development [2] - The company has utilized NVIDIA chips in some of its products and is actively seeking technology partners to promote the development of ultrasound artificial intelligence technology [2]

Group 1 - The global robotics industry is experiencing explosive growth, with the healthcare sector becoming a key battleground for technological integration [1] - Xiangsheng Medical has launched the "Breast Artificial Intelligence Ultrasound Robot" system, addressing the screening challenges of breast cancer, the most prevalent cancer globally [2] - The new system integrates ultrasound, robotics, and artificial intelligence, enabling large-scale patient scanning and data management [2] Group 2 - Xiangsheng Medical has developed 61 core technologies, including harmonic imaging and high-speed blood flow detection systems, demonstrating its deep technological accumulation over nearly 30 years [2] - The company’s products have received international certifications such as EU CE and US FDA, indicating its research and development level is at the international advanced level [2] - The company has established strategic partnerships with several international medical giants through an ODM model, contributing to its revenue [2] Group 3 - Xiangsheng Medical is pioneering the ultrasound AI diagnostic field in China, creating a complete value chain of "precise screening - intelligent diagnosis - personalized rehabilitation" [3] - The company employs a dual-engine approach of "ultrasound artificial intelligence + specialized models" to build a technological moat [3] - The ultrasound imaging equipment market in China is projected to grow from 10.4 billion yuan in 2021 to 17.1 billion yuan by 2026, with a compound annual growth rate of 10.5% [3]

截至2025年8月15日收盘，祥生医疗（688358）报收于33.25元，较上周的33.64元下跌1.16%。本周，祥 生医疗8月12日盘中最高价报35.73元。8月15日盘中最低价报32.03元。祥生医疗当前最新总市值37.28亿 元，在医疗器械板块市值排名100/126，在两市A股市值排名4001/5152。 公司公告汇总 祥生医疗股东减持股份计划公告显示，实际控制人、董事长及高级管理人员莫若理女士直接持有公司股 份26,460,000股，占公司总股本的23.60%，均为无限售流通股。莫若理女士计划在公告披露之日起15个 交易日后的3个月内，通过集中竞价或大宗交易的方式减持合计不超过所持公司股份3,363,735股，即不 超过祥生医疗总股本的3.00%。其中以集中竞价方式拟减持股份数量为合计不超过1,121,245股，即不超 过祥生医疗总股本的1.00%；以大宗交易方式拟减持股份数量为合计不超过2,242,490股，即不超过祥生 医疗总股本的2.00%。减持原因为股东自身资金需求及资金规划。本次减持计划不会对公司治理结构、 股权结构及持续经营产生影响。在减持期间，股东将根据市场情况、公司股价等因素决定是否 ...

Group 1 - The stock price of Xiangsheng Medical is 33.25 yuan, down 0.60 yuan or 1.77% from the previous trading day [1] - The opening price was 33.06 yuan, with a high of 33.40 yuan and a low of 32.03 yuan, and the trading volume reached 40,700 lots with a transaction value of 133 million yuan [1] - Xiangsheng Medical operates in the medical device industry, focusing on the research, manufacturing, and sales of ultrasound medical imaging equipment, with 99.88% of its revenue in 2024 coming from this sector [1] Group 2 - On August 14, the company announced that its actual controller, Mo Ruoli, plans to reduce his holdings by up to 3% of the total share capital, which amounts to 3.36 million shares, between September 5 and December 4, 2025 [1] - Mo Ruoli currently holds 23.6% of the company's shares, with plans to reduce up to 1.12 million shares through centralized bidding and 2.24 million shares through block trading [1] - On the same day, the net outflow of main funds was 16.81 million yuan, accounting for 0.45% of the circulating market value, with a cumulative net outflow of 18.32 million yuan over the past five trading days, representing 0.49% of the circulating market value [1]